{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:21:37Z","timestamp":1787775697426,"version":"build-2784847793"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Pulmonary sarcomatoid carcinoma (PSC) is a rare lung cancer characterized by early metastasis and invasion. It is predominantly diagnosed at a locally advanced or metastatic stage, hindering the possibility of surgical intervention. However, a standard treatment for advanced PSC remains unestablished. This study evaluated the effects of chemotherapy and immunotherapy-based strategies in patients with advanced PSC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The Surveillance, Epidemiology, and End Results (SEER) database and data from three cancer centers were used in this retrospective study. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan\u2013Meier method. Univariate and multivariate analyses were conducted to identify the prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In total, 202 patients with stage IV PSC were identified from the SEER database (median OS, 5 months). The median follow-up time of patients from the three centers was 18.8 months. First-line treatment with immunotherapy-based regimens and chemotherapy was administered to 12 and 27 patients, respectively. The median PFS was 2.1 and 7.3 months [hazard ratio (HR), 0.16; 95% confidence interval (CI), 0.06\u20130.40;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001], while the median OS was 3.6 and 21.4 months (HR, 0.21; 95% CI, 0.09\u20130.50;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) in the chemotherapy and immune-based groups, respectively. The immunotherapy-based regimen was an independent prognostic factor for PFS (HR, 0.21; 95% CI, 0.08\u20130.55;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001) and OS (HR, 0.20; 95% CI, 0.08\u20130.49;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Conventional chemotherapy offered limited benefits in patients with advanced PSC; however, those who received first-line immunotherapy-based regimens exhibited significantly improved responses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_479_24","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T12:02:15Z","timestamp":1736510535000},"page":"2110-2117","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of clinical outcomes in patients with advanced pulmonary sarcomatoid carcinoma treated with immunotherapy-based regimens or chemotherapy: A study based on the SEER database and multicentric real-world settings"],"prefix":"10.4103","volume":"20","author":[{"given":"Duanyang","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue\u2019e","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Second Affiliated Hospital of Nanchang University, Nanchang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Gannan Medical College, Ganzhou, Jiangxi Province, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Ganzhou People\u2019s Hospital, Ganzhou, Jiangxi Province, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"R1-20250110","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.4103\/jcrt.jcrt_2352_22","article-title":"Prediction of lymph node metastasis of lung squamous cell carcinoma by machine learning algorithm classifiers","volume":"19","author":"Li","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R2-20250110","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.surg.2012.05.007","article-title":"Outcomes of sarcomatoid carcinoma of the lung:A surveillance, epidemiology, and end results database analysis","volume":"152","author":"Yendamuri","year":"2012","journal-title":"Surgery"},{"key":"R3-20250110","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors:Impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R4-20250110","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1078-0432.CCR-18-2364","article-title":"An Epithelial-to-mesenchymal transcriptional switch triggers evolution of pulmonary sarcomatoid carcinoma (PSC) and identifies dasatinib as new therapeutic option","volume":"25","author":"Manzotti","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R5-20250110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2007.05.006","article-title":"Palliative chemotherapy for pulmonary pleomorphic carcinoma","volume":"58","author":"Bae","year":"2007","journal-title":"Lung Cancer"},{"key":"R6-20250110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.21037\/atm-20-6213","article-title":"Clinicopathological characteristics and prognostic factors of pulmonary sarcomatoid carcinoma:A large population analysis","volume":"9","author":"Gang","year":"2021","journal-title":"Ann Transl Med"},{"key":"R7-20250110","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.athoracsur.2020.02.071","article-title":"Pulmonary sarcomatoid carcinoma:Experience from SEER database and Shanghai pulmonary hospital","volume":"110","author":"Sun","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"R8-20250110","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/tlcr-20-960","article-title":"Preoperative systemic immune-inflammation index predicts survival and recurrence in patients with resected primary pulmonary sarcomatoid carcinoma","volume":"10","author":"Zeng","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"R9-20250110","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.jtcvs.2021.01.081","article-title":"Adjuvant chemotherapy for pulmonary sarcomatoid carcinoma:A retrospective analysis of the National Cancer Database","volume":"163","author":"Abdallah","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R10-20250110","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cllc.2016.03.001","article-title":"Characteristics and clinical outcomes of sarcomatoid carcinoma of the lung","volume":"17","author":"Ung","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"R11-20250110","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10238-018-0517-2","article-title":"A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung","volume":"18","author":"Hou","year":"2018","journal-title":"Clin Exp Med"},{"key":"R12-20250110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.lungcan.2012.10.010","article-title":"Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy","volume":"79","author":"Giroux","year":"2013","journal-title":"Lung Cancer"},{"key":"R13-20250110","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J Clin Oncol"},{"key":"R14-20250110","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4103\/jcrt.jcrt_723_23","article-title":"Immunotherapy for early-stage non-small cell lung cancer:A system review","volume":"19","author":"Gao","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R15-20250110","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1016\/j.cllc.2018.12.013","article-title":"Immune checkpoint blockade is associated with durable responses in pulmonary sarcomatoid carcinoma","volume":"20","author":"Sukrithan","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"R16-20250110","doi-asserted-by":"crossref","first-page":"104992","DOI":"10.1016\/j.oraloncology.2020.104992","article-title":"Successful treatment of advanced pulmonary sarcomatoid carcinoma with the PD-1 inhibitor toripalimab:A case report","volume":"112","author":"Jiao","year":"2021","journal-title":"Oral Oncol"},{"key":"R17-20250110","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.lungcan.2021.03.019","article-title":"Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib","volume":"155","author":"Luo","year":"2021","journal-title":"Lung Cancer"},{"key":"R18-20250110","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/j.cllc.2020.02.022","article-title":"Relationship between programmed death receptor-ligand 1 expression and response to checkpoint inhibitor immunotherapy in pulmonary sarcomatoid carcinoma:A pooled analysis","volume":"21","author":"Babacan","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"R19-20250110","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2020.01.014","article-title":"Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma","volume":"15","author":"Domblides","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R20-20250110","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"R21-20250110","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"R22-20250110","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL):A randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R23-20250110","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"key":"R24-20250110","doi-asserted-by":"crossref","DOI":"10.4103\/jcrt.jcrt_721_21","article-title":"First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer:A classical and network meta-analysis","volume":"19","author":"Mutlu","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R25-20250110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2020.03.029","article-title":"Outstanding clinical efficacy of PD-1\/PD-L1 inhibitors for pulmonary pleomorphic carcinoma","volume":"132","author":"Lee","year":"2020","journal-title":"Eur J Cancer"},{"key":"R26-20250110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lungcan.2016.05.013","article-title":"Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages","volume":"98","author":"Vieira","year":"2016","journal-title":"Lung Cancer"},{"key":"R27-20250110","doi-asserted-by":"crossref","first-page":"976739","DOI":"10.3389\/fimmu.2022.976739","article-title":"Immunophenotyping of pulmonary sarcomatoid carcinoma","volume":"13","author":"Ma","year":"2022","journal-title":"Front Immunol"},{"key":"R28-20250110","doi-asserted-by":"crossref","first-page":"17588359221136759","DOI":"10.1177\/17588359221136759","article-title":"Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma:A multicentric real-world study","volume":"14","author":"Zhou","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"R29-20250110","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC","volume":"16","author":"Chu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R30-20250110","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.21037\/tlcr-22-438","article-title":"Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer:A three-armed prospective study","volume":"11","author":"Chu","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"R31-20250110","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00262-022-03259-5","article-title":"Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients","volume":"72","author":"Yuan","year":"2023","journal-title":"Cancer Immunol Immunother"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_479_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:39:28Z","timestamp":1787773168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_479_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_479_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2024-03-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}